KMT2A and leukemia: Our findings support the presence of metabolic variability within MLL-r leukemia that might partly underlie the postulated heterogeneity of the disease, providing a rationale for the development of therapeutic approaches individually tailored toward specific disease subtypes, in order to achieve significant overall improvement of patient survival rates.